Frontiers in Oncology最新文献

{"title":"Evolving paradigms in prostate cancer screening: a decade of bibliometric insights and technological advancements.","authors":"Keqiang Chai, Changhong Xu, Jiangwei Man, Yun Deng, Li Yang","doi":"10.3389/fonc.2025.1511880","DOIUrl":"10.3389/fonc.2025.1511880","url":null,"abstract":"<p><strong>Objective: </strong>Prostate cancer is a major threat to global male health. This study uses bibliometric methods to analyze the dynamics and trends in prostate cancer screening research, with the aim of optimizing screening strategies and informing policy decisions.</p><p><strong>Methods: </strong>Utilizing the Web of Science Core Collection database, this study retrieved prostate cancer screening-related literature published between 2014 and 2024, totaling 5,409 articles. Data processing and analysis were conducted using CiteSpace and the Bibliometrix R package, including citation network analysis, co-word analysis, cluster analysis, and trend analysis.</p><p><strong>Results: </strong>The analysis revealed the following key findings: (1) Global literature on prostate cancer screening has grown annually, with the United States, Europe, and China leading research activity; (2) Research hotspots include the risks and benefits of prostate-specific antigen (PSA) testing, MRI-based screening technologies, and the use of molecular and genetic biomarkers; (3) Emerging technologies, such as machine learning and nanodiagnostic techniques, are enhancing diagnostic precision and reducing overdiagnosis; (4) Network analysis of collaborations reveals a shift toward transnational and interdisciplinary research, particularly in integrating biomedical and computer science to drive rapid advancements in screening technologies.</p><p><strong>Conclusion: </strong>This study confirms the ongoing vibrancy and technological advancement in the global field of prostate cancer screening research, emphasizing the trend towards precision medicine. Future development of prostate cancer screening strategies should focus on risk-adapted screening and the application of novel biomarkers to optimize screening outcomes and reduce unnecessary medical interventions.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1511880"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning model for the early prediction of pathologic response following neoadjuvant chemotherapy in breast cancer patients using dynamic contrast-enhanced MRI.","authors":"Meng Lv, BinXin Zhao, Yan Mao, Yongmei Wang, Xiaohui Su, Zaixian Zhang, Jie Wu, Xueqiang Gao, Qi Wang","doi":"10.3389/fonc.2025.1491843","DOIUrl":"10.3389/fonc.2025.1491843","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate the diagnostic accuracy of various deep learning methods on DCE-MRI, in order to provide a simple and accessible tool for predicting pathologic response of NAC in breast cancer patients.</p><p><strong>Methods: </strong>In this study, we enrolled 313 breast cancer patients who had complete DCE-MRI data and underwent NAC followed by breast surgery. According to Miller-Payne criteria, the efficacy of NAC was categorized into two groups: the patients achieved grade 1-3 of Miller-Payne criteria were classified as the non-responders, while patients achieved grade 4-5 of Miller-Payne criteria were classified as responders. Multiple deep learning frameworks, including ViT, VGG16, ShuffleNet_v2, ResNet18, MobileNet_v2, MnasNet-0.5, GoogleNet, DenseNet121, and AlexNet, were used for transfer learning of the classification model. The deep learning features were obtained from the final fully connected layer of the deep learning models, with 256 features extracted based on DCE-MRI data for each patient of each deep learning model. Various machine-learning techniques, including support vector machine (SVM), K-nearest neighbor (KNN), RandomForest, ExtraTrees, XGBoost, LightGBM, and multiple-layer perceptron (MLP), were employed to construct classification models.</p><p><strong>Results: </strong>We utilized various deep learning models to extract features and subsequently constructed machine learning models. Based on the performance of different machine learning models' AUC values, we selected the classifiers with the best performance. ResNet18 exhibited superior performance, with an AUC of 0.87 (95% CI: 0.82 - 0.91) and 0.87 (95% CI: 0.78 - 0.96) in the train and test cohorts, respectively.</p><p><strong>Conclusions: </strong>Using pre-treatment DCE-MRI images, our study trained multiple deep models and developed the best-performing DLR model for predicting pathologic response of NAC in breast cancer patients. This prognostic tool provides a dependable and impartial basis for effectively identifying breast cancer patients who are most likely to benefit from NAC before its initiation. At the same time, it can also identify those patients who are insensitive to NAC, allowing them to proceed directly to surgical treatment and prevent the risk of losing the opportunity for surgery due to disease progression after NAC.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1491843"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A patient with penile metastasis secondary to small cell lung cancer successfully treated with PD-1 inhibitors and chemotherapy: a case report and literature review.","authors":"Kai-Cong Zhang, Wei-Jun Li, Hui-Xin Xu, Hui-Min Liang, Qiong Yang","doi":"10.3389/fonc.2025.1484365","DOIUrl":"10.3389/fonc.2025.1484365","url":null,"abstract":"<p><strong>Background: </strong>Penile metastasis is an uncommon condition, with most primary malignancies originating in the abdominal cavity and pelvis. There have been very few reported cases originating from lung cancer, most of squamous cell carcinoma without small cell lung cancer.</p><p><strong>Methods: </strong>We presented a case of penile metastasis secondary to small cell lung cancer, along with a review of relevant literature from the CNKI database.</p><p><strong>Results: </strong>A 73-year-old male presented with a one-month history of palpable swelling in the penis without any chest symptoms. Beside penile lesion, PET/CT imaging also revealed a lesion in the left lobe of the lung, as well as multiple enlarged lymph nodes in the left hilum, mediastinum, and left supraclavicular fossa. Fiberoptic biopsy confirmed small cell lung cancer for the pulmonary mass, while biopsies of the penile mass confirmed metastatic small cell carcinoma. The patient received first-line treatment of 6 cycles of PD-1 inhibitor (Toripalimab) combined with etoposide and cisplatin, achieving a partial response (PR). Subsequently, second-line therapy of etoposide and cisplatin regimen and later-line therapies of Irinotecan followed by Anlotinib were administered. The overall survival was approximately 2 years.</p><p><strong>Conclusion: </strong>Penile metastasis from small cell lung cancer is extremely rare. Treatment strategies based on guidelines for small cell lung cancer had been proven effective approaches.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1484365"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in the application of artificial intelligence in the field of colorectal cancer.","authors":"Mengying Zhu, Zhenzhu Zhai, Yue Wang, Fang Chen, Ruibin Liu, Xiaoquan Yang, Guohua Zhao","doi":"10.3389/fonc.2025.1499223","DOIUrl":"10.3389/fonc.2025.1499223","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a prevalent malignant tumor in the digestive system. As reported in the 2020 global cancer statistics, CRC accounted for more than 1.9 million new cases and 935,000 deaths, making it the third most common cancer worldwide in terms of incidence and the second leading cause of cancer-related deaths globally. This poses a significant threat to global public health. Early screening methods, such as fecal occult blood tests, colonoscopies, and imaging techniques, are crucial for detecting early lesions and enabling timely intervention before cancer becomes invasive. Early detection greatly enhances treatment possibilities, such as surgery, radiation therapy, and chemotherapy, with surgery being the main approach for treating early-stage CRC. In this context, artificial intelligence (AI) has shown immense potential in revolutionizing CRC management, serving as one of the most effective screening tools. AI, utilizing machine learning (ML) and deep learning (DL) algorithms, improves early detection, diagnosis, and treatment by processing large volumes of medical data, uncovering hidden patterns, and forecasting disease development. DL, a more advanced form of ML, simulates the brain's processing power, enhancing the accuracy of tumor detection, differentiation, and prognosis predictions. These innovations offer the potential to revolutionize cancer care by boosting diagnostic accuracy, refining treatment approaches, and ultimately enhancing patient outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1499223"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Thymic neuroendocrine tumor with metastasis to the breast causing ectopic Cushing's syndrome.","authors":"Aleksandra Zdrojowy-Wełna, Marek Bolanowski, Joanna Syrycka, Aleksandra Jawiarczyk-Przybyłowska, Justyna Kuliczkowska-Płaksej","doi":"10.3389/fonc.2025.1492187","DOIUrl":"10.3389/fonc.2025.1492187","url":null,"abstract":"<p><p>Ectopic adrenocorticotropic hormone secretion (EAS) is responsible for approximately 10%-18% of Cushing's syndrome cases. Thymic neuroendocrine tumors (NETs) comprise 5%-16% of EAS; therefore, they are very rare and the data about this particular tumors is scarce. We present a case of a 34-year-old woman with a rapid onset of severe hypercortisolism in April 2016. After initial treatment with a steroid inhibitor (ketoconazole) and diagnostics including ⁶⁸Ga DOTA-TATE PET/CT, it was shown to be caused by a small thymic NET. After a successful surgery and the resolution of all symptoms, there was a recurrence after 5 years of observation caused by a metastasis to the breast, shown in the ⁶⁸Ga DOTA-TATE PET/CT result and confirmed with a breast biopsy. Treatment with a steroid inhibitor (metyrapone) and tumor resection were again curative. The last disease relapse appeared 7 years after the initial treatment, with severe hypercortisolism treated with osilodrostat. There was a local recurrence in the mediastinum, and a thoracoscopic surgery was performed with good clinical and biochemical effect. The patient remains under careful follow-up. Our case stays in accordance with recent literature data, showing that patients with thymic NETs are younger than previously considered and that the severity of hypercortisolism does not correlate with the tumor size. The symptoms of EAS associated with thymic NET may develop rapidly and may be severe as in our case. Nuclear medicine improves the effectiveness of the tumor search, which is crucial in successful EAS therapy. Our case also underlines the need for lifelong monitoring of patients with thymic NETs and EAS.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1492187"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CENP-H as a new prognostic biomarker for tumors: a real-world literature review.","authors":"Qiao Li, Yang Tang, Jie-Bin Zuo, Hao Han, Guang-Xu Tu, Cheng Chen","doi":"10.3389/fonc.2025.1521988","DOIUrl":"10.3389/fonc.2025.1521988","url":null,"abstract":"<p><p>Centromere protein H (CENP-H) is an important component of a functional centromere. Studies have demonstrated that CENP-H is overexpressed in renal cell, gastric, hypopharyngeal squamous cell, nasopharyngeal, endometrial, lung, cervical, esophageal, liver, colorectal, oral squamous cell, breast, and tongue carcinomas. CENP-H overexpression is positively correlated with a poor prognosis, pathological stage, T stage, and lymph node metastasis in patients with the above carcinomas. CENP-H can promote cancer growth and metastasis through PI3K/AKT, survivin, and mitochondrial apoptosis signaling mechanisms, and it can be regulated by long non-coding ribonucleic acid (lncRNA) plasmacytoma variant translocation 1 (PVT1)/miR-612, Sp1, or Sp3. This review aims to summarize the expression of CENP-H, the relationship between CENP-H expression and prognostic features, growth and metastasis of cancer in patients, as well as the mechanism of CENP-H in cancer. It also proposes a new candidate molecule for treating patients with cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1521988"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compound cancer with small cell carcinoma and mucinous adenocarcinoma of the ovary: a case report and literature review.","authors":"Wan Peng, Hui Hu, Genhua Huang, Xiaoyun Wu, Yichen Zhu, Tian Yang, Xin Tao, Buzhen Tan","doi":"10.3389/fonc.2025.1500088","DOIUrl":"10.3389/fonc.2025.1500088","url":null,"abstract":"<p><p>Primary small cell carcinoma of the ovary is an extremely rare and highly malignant ovarian malignancy. The tissue origin of this type of cancer is still unclear, and it is characterized by rapid progression and a discouraging prognosis. The clinical presentation of small cell carcinoma of the ovary lacks specificity, and there are currently no effective treatment options available. Therefore, it is crucial to improve the understanding and identification of this disease. In this paper, we present a case of composite small cell carcinoma of the ovary with mucinous adenocarcinoma and provide a comprehensive review of the relevant literature.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1500088"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging roles of intratumoral microbiota: a key to novel cancer therapies.","authors":"Pengzhong Fang, Jing Yang, Huiyun Zhang, Diankui Shuai, Min Li, Lin Chen, Liping Liu","doi":"10.3389/fonc.2025.1506577","DOIUrl":"10.3389/fonc.2025.1506577","url":null,"abstract":"<p><p>Microorganisms, including bacteria, viruses, and fungi, have been found to play critical roles in tumor microenvironments. Due to their low biomass and other obstacles, the presence of intratumor microbes has been challenging to definitively establish. However, advances in biotechnology have enabled researchers to reveal the association between intratumor microbiota and cancer. Recent studies have shown that tumor tissues, once thought to be sterile, actually contain various microorganisms. Disrupted mucosal barriers and adjacent normal tissues are important sources of intratumor microbiota. Additionally, microbes can invade tumors by traveling through the bloodstream to the tumor site and infiltrating through damaged blood vessels. These intratumor microbiota may promote the initiation and progression of cancers by inducing genomic instability and mutations, affecting epigenetic modifications, activating oncogenic pathways, and promoting inflammatory responses. This review summarizes the latest advancements in this field, including techniques and methods for identifying and culturing intratumor microbiota, their potential sources, functions, and roles in the efficacy of immunotherapy. It explores the relationship between gut microbiota and intratumor microbiota in cancer patients, and whether altering gut microbiota might influence the characteristics of intratumor microbiota and the host immune microenvironment. Additionally, the review discusses the prospects and limitations of utilizing intratumor microbiota in antitumor immunotherapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1506577"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study.","authors":"Junfeng Bu, Zihan Li, Die Hu, Ling Lan, Jiwei Huang, Xin Wang, Qiu Li, Jin Zhou, Yong Zeng","doi":"10.3389/fonc.2025.1554711","DOIUrl":"10.3389/fonc.2025.1554711","url":null,"abstract":"<p><strong>Background: </strong>Unresectable hepatocellular carcinoma (HCC) presents significant treatment challenges. While locoregional therapies (LT) and tyrosine kinase inhibitors (TKI) offer some benefits, prognosis remains poor. Immune checkpoint inhibitors (ICI) have shown promise in other oncological settings, suggesting potential benefits in HCC treatment regimens.</p><p><strong>Methods: </strong>This retrospective study analyzed 232 patients diagnosed with unresectable HCC at West China Hospital from January 2019 to December 2023. Patients were categorized into two treatment groups: LT+TKI and LT+TKI+ICI. All patients underwent standardized locoregional treatments and first-line TKIs, with the latter group also receiving ICIs. The primary endpoints measured were overall survival (OS) and progression-free survival (PFS). Survival analysis utilized Kaplan-Meier estimates and Cox regression models.</p><p><strong>Results: </strong>The LT+TKI+ICI group demonstrated significantly improved survival outcomes compared to the LT+TKI group. Median OS was 28 ± 3.9 months in the LT+TKI+ICI group versus 21 ± 3.0 months in the LT+TKI group, with corresponding 6-, 12-, and 24-month OS rates of 96.8%, 79.3%, and 59.4% versus 85.8%, 71.5%, and 44.1%, respectively (HR, 0.64; 95% CI, 0.449-0.913; P = 0.014). Median PFS also favored the LT+TKI+ICI group (11 ± 1.1 months vs. 7 ± 0.76 months; HR, 0.60; 95% CI, 0.452-0.805; P<0.001). Multivariable analysis identified LT+TKI, vascular invasion, and metastasis as independent risk factors for poorer survival outcomes.</p><p><strong>Conclusions: </strong>Adding ICI to LT and TKI significantly extends both OS and PFS in patients with unresectable HCC. These findings suggest that integrating ICI into treatment protocols could be beneficial in managing unresectable HCC, particularly for patients with vascular invasion.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1554711"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of magnetic resonance imaging for malignant ovarian tumors mis-subclassified by the ultrasound-based ADNEX model.","authors":"Meijiao Jiang, Congcong Yuan, Siwei Lu, Yunkai Zhu, Caiting Chu, Wenhua Li","doi":"10.3389/fonc.2025.1406735","DOIUrl":"10.3389/fonc.2025.1406735","url":null,"abstract":"<p><strong>Objective: </strong>Accurately predicting metastatic cancer to the adnexa, stage I and advanced ovarian cancer before surgery is crucial. The ADNEX model, based on ultrasound, is currently the only prediction model that can differentiate between these types. This study aims to analyze MRI features and diagnostic value in malignant ovarian tumors mis-subclassified by the ADNEX model, considering their diverse histopathologic types.</p><p><strong>Methods: </strong>From January 2018 to September 2022, 164 patients with pathologically confirmed ovarian malignancies were selected from those who were examined by ultrasound. The clinical and MRI characteristics of 51 patients mis-subclassified by the ADNEX model were compared with histopathological types.</p><p><strong>Results: </strong>A total of 30 were confirmed with primary ovarian cancer (5 with HGSOC, 14 with CCC, 2 with EC, 4 with MC, 2 with GCT, 1 with YST, 1 with immature teratoma, and 1 with dysgerminoma). There were 21 patients who had metastatic ovarian tumors (10 with colorectal cancer, 4 with gastric cancer, 2 with uterine cervical cancer, 3 with endometrial cancer, 1 with breast cancer, and 1 with LAMN). The only significant difference between the two groups was in CEA. The mean diameters of the primary and metastatic ovarian tumors were 10.29 cm (range: 3.61 cm-26.02 cm) and 8.58 cm (range: 3.10 cm-20.30 cm), respectively. A total of 42 masses were lobulated (82.35%, 42/51), and 26 masses were solid-cystic (26/51, 50.98%). There was a significant difference between CCC and other tumors, with mean ADC values of 1.01 × 10^-3 mm²/s (range: 0.68-1.28×10^-3 mm²/s) and 0.74×10^-3 mm²/s (range: 0.48-0.99×10^-3 mm²/s), respectively (P=0.000). A total of 50 masses presented isointense-T1, hyperintense-T2, and hyperintense-DWI signal on MRI (50/51,98.04%). There were 33 masses that showed intensive enhancement (33/51,64.71%). There were 17 masses who had necrosis (17/51, 33.33%), with the majority being HGSOC and ovarian metastases from colorectal and gastric cancers (12/17, 70.59%). There were 19 masses that presented hemorrhage (19/51,37.25%), with the majority being CCC (10/19, 52.63%). A total of 46 masses were diagnosed correctly by MRI (46/51,90.20%). There were 35 and 15 masses that were rated as O-RADS score 5 and score 4, respectively. One mass was rated as score 3.</p><p><strong>Conclusions: </strong>DWI signal, ADC value, degree of enhancement, and characteristic components within the mass on MRI can provide supplementary information for malignant ovarian tumors mis-subclassified by the ADNEX model.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1406735"},"PeriodicalIF":3.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}